We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
Fields »
 

Field

Term
Gene name

Class

Subclass

Chromosome

External id

In atlas

Reliability

Reliability

Reliability

Validation

Method

Validation

Method

Validation

Method

Validation

Location

Searches

Tissue

Cell type

Expression

Tissue

Specificity

Cell line

Specificity

Cancer

Specificity

Tissue

Detectable

Cell line

Detectable

Cancer

Detectable

Cancer

Prognosis

Category

Score

Score

Score

Antibodies

Column

 
 
ABOUT
HELP
BLOG
  • THE HUMAN PROTEOME
  • THE HUMAN TISSUES
  • THE HUMAN CELL
  • HUMAN PATHOLOGY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
    • NEWS
    • BLOG
    • EVENTS
    • PRESS ROOM
    • LEARN
    • DICTIONARY
    • METHODS
    • CELL LINES
  • THE PROJECT
  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • PUBLICATION DATA
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • LINKS
  • CONTACT
  • TECHNICAL DATA
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • DOWNLOADABLE DATA
  • HELP & FAQ
  • LICENCE & CITATION
  • PRIVACY STATEMENT
  • RELEASE HISTORY
ANXA1
  • premium

    TISSUE

  • premium

    CELL

  • PATHOLOGY

PATHOLOGY ATLAS MELANOMA

GENE/PROTEIN

Antibody validation

Dictionary

Melanoma

MELANOMA - Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival, using best separation (to the left) and median separation (to the right). Patients were divided based on level of expression into one of the two groups "low" or "high". Below each Kaplan-Meier plot, corresponding expression cutoff, 5-year survival for patients with high expression, 5-year survival for patients with low expression and log-rank P value are displayed. For melanoma and glioma, 3-year survival is shown. The survival analysis is described in Assays & Annotation.

The tabs at the top of the survival analysis section can be used to switch between the different cancer subtypes.

Best separation

Median separation

Expression cutoffi

5-year survival for patients with higher expression than the expression cutoff.

102.1 FPKM 58.8 FPKM

3-year survival highi

5-year survival for patients with higher expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

62% 26%

3-year survival lowi

5-year survival for patients with lower expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

30% 58%

Log-rank P valuei

Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.

1.30e-1 3.50e-1

Interactive survival scatter plot (individual patient data)i

The Scatter Survival plot shows the clinical status for all individuals in the patient cohort, based on the same data as in the Kaplan-Meier plots. Living patients are shown in blue and deceased patients in red. The x-axis shows the expression levels (FPKM) of the investigated gene at the time of diagnosis and the y-axis shows the number of years of survival (living years) after the diagnosis.

Individual patient data is displayed in an interactive plot and can be filtered by clicking on one or several category buttons to the left. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be changed to "x linear" by clicking on the "x log" button on the left. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.




Stage:



TCGA RNA samplesi

RNA-seq data is reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .

Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.

Average FPKM

71.0

Number of samples

102

Samples

Sample

Description

FPKM

TCGA-XV-A9W5-01A 51 years, male, white, stage:i/ii nos 367.5
TCGA-EB-A41A-01A 90 years, male, white, stage:iic 252.8
TCGA-GN-A26C-01A 77 years, male, white, stage:iiic 208.2
TCGA-EB-A550-01A 75 years, female, white, stage:iic 205.1
TCGA-EB-A42Z-01A 49 years, male, asian, stage:iiic 196.2
TCGA-BF-A3DJ-01A 36 years, female, white, stage:iiib 192.5
TCGA-EB-A51B-01A 53 years, male, white, stage:iic 183.2
TCGA-BF-A1Q0-01A 80 years, male, white, stage:iic 179.9
TCGA-XV-A9W2-01A 81 years, male, white, stage:i 177.1
TCGA-FR-A2OS-01A 49 years, female, white, stage:iic 170.8
TCGA-FR-A3R1-01A 69 years, male, white, stage:iic 165.5
TCGA-BF-A1PV-01A 74 years, female, white, stage:iic 146.5
TCGA-ER-A196-01A 64 years, female, white, stage:iic 140.9
TCGA-BF-AAOU-01A 73 years, female, white, stage:iic 137.5
TCGA-XV-AAZV-01A 56 years, female, white, stage:ii 128.0
TCGA-EB-A85I-01A 66 years, male, white, stage:iic 126.1
TCGA-EB-A82B-01A 58 years, female, asian, stage:iii 123.8
TCGA-FS-A1ZN-01A 43 years, male, white, stage:iiia 123.3
TCGA-EB-A44P-01A 58 years, female, white, stage:iic 121.9
TCGA-EB-A24D-01A 72 years, male, white, stage:iiib 119.6
TCGA-EB-A299-01A 63 years, male, white, stage:iia 118.9
TCGA-EB-A3Y6-01A 56 years, female, white, stage:iic 111.6
TCGA-GN-A4U5-01A 61 years, female, white, stage:ib 106.7
TCGA-ER-A2NB-01A 57 years, male, white, stage:iiib 97.5
TCGA-EB-A5UM-01A 48 years, female, white, stage:iic 97.5
TCGA-EB-A5SE-01A 73 years, male, white, stage:iib 96.4
TCGA-BF-A5ES-01A 76 years, female, white, stage:iic 91.8
TCGA-EB-A82C-01A 70 years, female, asian, stage:iic 89.7
TCGA-EB-A4P0-01A 82 years, male, white, stage:iic 89.3
TCGA-XV-AAZW-01A 62 years, female, white, stage:ii 87.0
TCGA-EB-A3XE-01A 77 years, female, white, stage:iia 86.8
TCGA-EB-A44N-01A 59 years, male, white, stage:iic 86.0
TCGA-BF-A5EQ-01A 63 years, male, white, stage:iic 83.3
TCGA-EB-A3XF-01A 57 years, male, white, stage:iic 81.6
TCGA-BF-AAOX-01A 83 years, male, white, stage:iic 80.4
TCGA-EB-A4IQ-01A 42 years, female, asian, stage:iiib 79.4
TCGA-EB-A5VU-01A 56 years, male, asian, stage:iiib 78.5
TCGA-GN-A263-01A 24 years, male, white, stage:iv 77.9
TCGA-ER-A19K-01A 79 years, female, white, stage:iic 77.9
TCGA-EB-A24C-01A 56 years, male, white 77.3
TCGA-D3-A5GT-01A 43 years, male, white, stage:iiic 74.1
TCGA-GF-A769-01A 39 years, male, white, stage:iic 72.3
TCGA-BF-A1PU-01A 46 years, female, white, stage:iic 68.5
TCGA-BF-A3DN-01A 81 years, female, white, stage:iiic 67.8
TCGA-EB-A4XL-01A 56 years, female, white, stage:iic 66.4
TCGA-GF-A2C7-01A 48 years, male, white, stage:iic 66.0
TCGA-D9-A3Z4-01A 54 years, male, white, stage:iiic 63.3
TCGA-EB-A6QZ-01A 76 years, female, white, stage:iia 62.0
TCGA-EB-A6R0-01A 58 years, female, white, stage:iic 61.7
TCGA-EB-A4IS-01A 77 years, male, white, stage:iib 61.7
TCGA-EB-A6QY-01A 71 years, male, white, stage:iic 60.9
TCGA-BF-AAP2-01A 62 years, male, white, stage:iib 56.8
TCGA-EB-A57M-01A 56 years, male, asian, stage:iiib 56.6
TCGA-EB-A3XB-01A 63 years, male, white, stage:ii 55.0
TCGA-BF-A1PX-01A 56 years, male, white, stage:iiib 52.9
TCGA-D9-A4Z5-01A 68 years, male, white, stage:iib 52.8
TCGA-EB-A3XC-01A 74 years, male, white, stage:iic 47.8
TCGA-EB-A551-01A 78 years, female, white, stage:iiic 46.8
TCGA-XV-A9VZ-01A 90 years, female, white, stage:ii 46.5
TCGA-EB-A3HV-01A 37 years, male, white, stage:iic 46.5
TCGA-FR-A728-01A 54 years, female, white, stage:iiib 46.1
TCGA-GN-A8LN-01A 68 years, male, white, stage:iic 44.0
TCGA-FW-A5DX-01A 71 years, male, white, stage:iiic 40.9
TCGA-FR-A726-01A 90 years, male, white, stage:iic 39.8
TCGA-BF-A5EO-01A 65 years, male, white, stage:iic 39.3
TCGA-D9-A4Z3-01A 73 years, female, white, stage:iiic 35.3
TCGA-HR-A5NC-01A 90 years, female 34.7
TCGA-IH-A3EA-01A 61 years, male, white, stage:iic 33.8
TCGA-BF-A1PZ-01A 71 years, female, white, stage:iib 33.7
TCGA-BF-A5EP-01A 75 years, female, white, stage:iiic 33.7
TCGA-EB-A4OZ-01A 42 years, female, white, stage:iiic 31.5
TCGA-EB-A3XD-01A 53 years, female, white, stage:iic 28.6
TCGA-BF-AAP7-01A 76 years, female, white, stage:iic 28.4
TCGA-EB-A42Y-01A 73 years, female, asian, stage:iic 27.4
TCGA-ER-A194-01A 77 years, male, white 26.8
TCGA-EB-A1NK-01A 48 years, male, white, stage:iic 25.8
TCGA-EB-A5SF-01A 78 years, female, white, stage:iic 23.1
TCGA-EB-A97M-01A 66 years, male, white, stage:iic 17.7
TCGA-BF-A9VF-01A 77 years, male, white, stage:iic 16.7
TCGA-EB-A85J-01A 66 years, female, white, stage:iib 16.2
TCGA-ER-A42H-01A 77 years, male, white 15.8
TCGA-WE-A8K4-01A 85 years, male, white, stage:iib 15.3
TCGA-EB-A5FP-01A 65 years, female, white, stage:iv 13.2
TCGA-D9-A4Z2-01A 50 years, male, white, stage:iiic 12.5
TCGA-BF-AAP4-01A 61 years, male, white, stage:iic 11.7
TCGA-ER-A19T-01A 51 years, male, white, stage:iv 10.0
TCGA-EB-A431-01A 34 years, male, white, stage:iic 9.8
TCGA-BF-A3DL-01A 84 years, female, white, stage:iiib 9.3
TCGA-BF-AAP1-01A 86 years, male, white, stage:iic 8.9
TCGA-BF-A5ER-01A 63 years, male, white, stage:iic 8.3
TCGA-EB-A41B-01A 76 years, female, white, stage:iic 8.2
TCGA-XV-AAZY-01A 76 years, female, white, stage:iiic 8.0
TCGA-YG-AA3N-01A 67 years, male, stage:iic 7.2
TCGA-EB-A44O-01A 69 years, male, white, stage:iib 6.2
TCGA-ER-A2NF-01A 53 years, male, white, stage:iiib 6.1
TCGA-BF-AAP8-01A 58 years, male, white, stage:iic 6.0
TCGA-BF-A3DM-01A 63 years, male, white, stage:iia 4.7
TCGA-EB-A553-01A 62 years, male, white, stage:iic 4.2
TCGA-BF-AAP6-01A 55 years, male, white, stage:iii 4.0
TCGA-EB-A3Y7-01A 86 years, female, white, stage:iiib 2.7
TCGA-DA-A960-01A 73 years, male, white, stage:iib 1.5
TCGA-EB-A4OY-01A 65 years, female, white, stage:iiib 0.7
Show all

MELANOMA - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

HPA011271

HPA011272

CAB013023

CAB035987

CAB058693

 Antibody staining
  High
  Medium
  Low
  Not detected
      
 Intensity
  Strong
  Moderate
  Weak
  Negative
      
 Quantity
  >75%
  75%-25%
  <25%
  Rare
  Negative
      
 Location
  Cytoplasmic/membranous,nuclear
  Cytoplasmic/membranous
  Nuclear
  None
      

Click images for details










































































































Contact

  • BLOG
  • PRESS ROOM
  • contact@proteinatlas.org

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • DOWNLOADABLE DATA

The Human Protein Atlas

  • ANTIBODY AVAILABILITY
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg foundation.